- Home
- BYFC vs ALDX Comparison
BYFC vs ALDX Comparison
Compare BYFC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | ALDX |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 89.3M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BYFC | ALDX |
|---|---|---|
| Price | $12.03 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 1.3K | ★ 660.9K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $173.08 | ★ N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $1.07 |
| 52 Week High | $12.35 | $5.93 |
Technical Indicators
Market Signals| Indicator | BYFC | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 46.93 |
| Support Level | $9.29 | $1.47 |
| Resistance Level | $12.31 | $1.60 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 25.34 | 48.28 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.